Beclometasone dipropionate - CAS:5534-09-8

您当前的位置：

Beclometasone dipropionate (Synonyms:二丙酸倍氯米松)

目录号 : KM4143 CAS No. : 5534-09-8 纯度 : 98%

Data Sheet 产品使用指南

Betamethasone dipropionate 是Betamethasone 的前体药物，是具有口服活性的、有效的糖皮质激素、具有抗炎和免疫抑制活性。Betamethasone 是有效的、LPS 诱导的炎症和 MMP 释放的抑制剂。

规格	价格	是否有货
250mg		In-stock
500mg	询价	In-stock
1g	询价	In-stock

加入购物车大包装询价

Other Forms of Rapamycin:

Dydrogesterone-D6 In-stock
Prostaglandin E1-d4 In-stock
Norcholic acid In-stock
Dicyclohexyl phthalate-3,4,5,6-d4 In-stock
Mebhydrolin napadisylate In-stock

KKL Med 的所有产品和服务仅用于科学研究，不能被用于人体，兽医，我们也不向个人提供产品和服务。

生物活性

Betamethasone dipropionate, the prodrug of Betamethasone, is an orally active and potent glucocorticoid with anti-inflammatory and immunosuppressive activity. Betamethasone appears to be an effective inhibitor of LPS-induced inflammation and MMP release.

体外研究

The Calcipotriol/Betamethasone combination significantly inhibits the secretion of IL-17A and TNF-α in psoriatic skin. Additionally, the two components show additive inhibitory effects on secretion of IL-23 and TNF-α by DCs, of IL-17A and TNF-α by both CD4+ and CD8+ T cells and reduced inflammatory responses in Th17-stimulated keratinocytes.

RT-PCR

Cell Line:	Pig and human skin.
Concentration:	1 μM.
Incubation Time:	24 h.
Result:	Additively inhibit expression of inflammatory cytokines in psoriasis skin explant cultures. Affected the activity of DCs resulting in a decreased secretion of TNF-α and IL-23.

体内研究

Betamethasone (5 mg/kg, orally) reduces the LPS-induced pulmonary inflammation and production of MMPs.

Animal Model:	Ten-week-old male Balb/c mice.
Dosage:	5 mg/kg (100 μg/ml for 60 min).
Administration:	Orally at 24 h and 1 h before the LPS aerosol.
Result:	Significantly (P < 0.05) inhibited the decrease of IL-10 level in BAL fluid induced by LPS exposure. Markedly reduced the release of both MMP-2 and MMP-9.

分子式

C₂₈H₃₇ClO₇

分子量

521.04

CAS号

5534-09-8

中文名称

二丙酸倍氯米松

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

溶解性数据

In Vitro:

DMSO : ≥ 100 mg/mL (191.92 mM)

H₂O : 1 mg/mL (1.92 mM; Need ultrasonic)

* "≥" means soluble, but saturation unknown.

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	1.9192 mL	9.5962 mL	19.1924 mL
5 mM	0.3838 mL	1.9192 mL	3.8385 mL
10 mM	0.1919 mL	0.9596 mL	1.9192 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% saline
Solubility: ≥ 2.5 mg/mL (4.80 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (4.80 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。
2.

请依序添加每种溶剂： 10% DMSO 90% corn oil
Solubility: ≥ 2.5 mg/mL (4.80 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (4.80 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。

临床试验

科研文献

纯度： 98%

Data Sheet

产品使用指南

摩尔计算器
稀释计算器

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

质量

浓度

体积

分子量*

重置计算

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2

浓度

体积

浓度

体积

重置计算

Other Forms of Rapamycin:

KKL 顾客使用本产品发表的 3 篇科研文献

The molarity calculator equation

The dilution calculator equation